SOUTH SAN FRANCISCO, Calif., May 23, 2024 Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune.
Truist Financial reiterated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $17.00 price target on the stock. A number of other analysts also recently weighed in on ALLO. Royal Bank of Canada reiterated an outperform rating […]
Autologous CAR-T Cell Therapy Market Size, Trends & Outlook 2024-2032 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at William Blair decreased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a research report issued on Tuesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.39) for the quarter, down from […]
Allogene Therapeutics (NASDAQ:ALLO) Price Target Cut to $9 00 by Analysts at HC Wainwright dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.